Alethio Therapeutics
Latest round
- Series A
Last raised
- Nov 2026
Total raised
- $90M
Investors
- 5
About Alethio Therapeutics
The biopharmaceutical company is developing targeted therapies for myeloproliferative neoplasms and will use the funds to advance its lead antibody ATX-011 through clinical studies.
Who invested in Alethio Therapeutics
5 investors across 1 round
See all investors in Alethio Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 5, 2026
Amount
$90M
Investors
Questions about Alethio Therapeutics
Who invested in Alethio Therapeutics?
Alethio Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Alethio Therapeutics raised?
Alethio Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Alethio Therapeutics last raise money?
Alethio Therapeutics's most recent round on record is a Series A, in Nov 2026.
What does Alethio Therapeutics do?
The biopharmaceutical company is developing targeted therapies for myeloproliferative neoplasms and will use the funds to advance its lead antibody ATX-011 through clinical studies.
Where is Alethio Therapeutics headquartered?
Alethio Therapeutics is headquartered in Oxford, United Kingdom.
Which VCs invest in companies like Alethio Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back health & biotech companies at Alethio Therapeutics's stage. Their profiles are linked below.
VCs backing health & biotech startups at Series A
Raising like Alethio Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.